Global liquid biopsies market
is anticipated to reach 5,958.3 million by 2030, according to a new report by
Grand View Research, Inc. As these less invasive biopsies are able to address a
number of significant challenges associated with conventional biopsies such as,
high level of invasiveness, incompleteness of cancer information that is
acquired, associated post-biopsy serious medical complications, and subsequent
cost inclusions. A growing need for more advanced, efficient and accurate
method which provides a holistic view of the tumor and metastasis is the prime
factor fueling rapid development of liquid biopsies.
The market has gained
considerable traction in the past couple of years. A number of clinical
research projects related to circulating tumor cells, and cell-free tumor DNA
have been initiated in the latter half of the past decade. As a result, there
are a number of ongoing clinical trials that are due to be completed between
post 2017-18. It is expected that upon successful completion, commercialization
of these assays and tests will provide the market a significant boost in
potential addressable target revenue and fuel growth through to 2030.
In depth research report on Liquid Biopsy Market
Further key findings from the report suggest:
·
In terms of applications,
therapy selection of metastatic cancers is the key area of liquid biopsy usage
as these provide significant insights into the unique genetic information
encoded in CTCs and ctDNAs. Furthermore, with the addition of more research
data reinforcing the usage of liquid biopsies over the coming years, it is
expected that their application for molecular monitoring of diseases will also
be a lucrative source of revenue through to 2030
·
Key biomarkers that any liquid
biopsy targets include circulating tumor cells, circulating tumor DNA and
exosomes that are macrovesicles containing tumor RNA, or tumor protein freely
circulating in the patient’s bloodstream. Assays for ctDNA are expected to
account for the largest share of revenue through to 2030 owing to the currently
present assays and expected number of products that are to be commercialized
over the coming decade.
·
Development of parallel
multi-gene analysis using next generation sequencing technology is the
underlying factor that has enabled oncologists to more efficiently sequence
ctDNA and gain insights related to cancer metastasis and the related mechanism.
This understanding provides a patient-centric systemic view of cancer and aids
in its long term monitoring.
·
North America, specifically the
U.S. accounts for the largest share of revenue for the development of liquid
biopsy market. The region was observed to account for around 50% of the global
potential in 2015 owing to the high number clinical development projects
underway for the commercialization of CTC and ctDNA assays till 2020.
Furthermore, throughout the forecast period, U.S. is expected to dominate
revenue generation owing to the dynamic nature & being the region of prime
activity, research and development with respect to liquid biopsy and next
generation sequencing technology.
·
Although, post successful
commercialization through to 2030, Asia Pacific is expected to be a lucrative
region for development as it is expected to be characterized by the presence of
a large patient population base, developing healthcare framework and growth in
integration of more advanced healthcare practices.
·
The market is in its developing
phase and is characterized by the presence of a number of relatively smaller
entities involved in innovation and new product development. Companies such as
Biocept, Adaptive Biotechnologies, NeoGenomics Laboratories, Guardant Health,
Qiagen, Personal Genome Diagnostics, Cynvenio, RainDance Technologies, and
Trovagene are operating in the space and have a number of commercialized assays
in their portfolios for liquid biopsy.
·
Furthermore, as this space has
a high lucrative potential, and is considerably influenced by the developments
in NGS technology, there are a number of major players that have ongoing
investigational & observational clinical trials and are due to be completed
by 2017 to 2019. Collectively, over 30 clinical trials are currently registered
as active by companies including Illumina, Foundation Medicine, Natera Inc.,
Roche, Sequenom, LabCorp, Epic Sciences, and Pathway Genomics in the U.S.
alone. Anticipated successful commercialization of these products is expected
to fuel growth over the forecast period.
Grand View Research has
segmented the liquid biopsy market on the basis of application, sample type,
biomarker, technology, and region:
Global Liquid Biopsy Outlook, by Application (Revenue, USD
Million, 2013 - 2030)
·
Therapy Selection for
Metastatic Breast Cancer (MBS)
·
Therapy Selection for Other
Metastatic Cancer
·
Molecular Health Monitoring
Global Liquid Biopsy, by Sample Type (Revenue, USD
Million, 2013 - 2030)
·
Blood Sample based
·
Urine Sample based
·
Other Bio Fluids (Tissue fluids
and Saliva) based
Global Liquid Biopsy Outlook, by Biomarker, (Revenue, USD
Million, 2013 - 2030)
·
Circulating Tumor Cells (CTC)
·
Circulating Tumor DNA (ctDNA)
·
Exosomes
Global Liquid Biopsy Outlook, by Biomarker, (Revenue, USD
Million, 2013 - 2030)
·
Multi - gene - parallel Analysis
(NGS)
·
Single Gene Analysis (PCR
Microarrays)
Global Liquid Biopsy Market, Regional Outlook (Revenue,
USD Million, 2013 - 2030)
·
North America
o
U.S.
o
Canada
·
Europe
o
Germany
o
UK
·
Asia Pacific
o
China
o
Japan
·
Latin America
o
Brazil
·
MEA
o
South Africa
Browse more research reports of this category:
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
For more market analysis reports, please visit: http://www.grandviewresearch.com/
No comments:
Post a Comment